• 1
    Early Breast Cancer Trialists’ Collaborative GroupEffects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer.N Engl J Med 1988; 319: 16811692
  • 2
    Early Breast Cancer Trialists’ Collaborative GroupSystemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy.Lancet 1992; 339: 1–15 and 7185
  • 3
    Catherino WH, Craig Jordan VA risk-benefit assessment of tamoxifen therapy.Drug Safety 1993; 8: 381397
  • 4
    Love RRTamoxifen therapy in primary breast cancer: biology, efficacy, and side effects.J Clin Oncol 1989; 7: 803815
  • 5
    McDonald CC,Stewart HJ for the Scottish Breast Cancer CommitteeBr Med J1991; 303: 435437
  • 6
    Rutqvist LE, Mattsson Afor the Stockholm Breast Cancer Study Group. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen.J Natl Cancer Inst 1993; 85: 13981406
  • 7
    Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking NAdjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies.J Natl Cancer Inst 1995; 87: 645651
  • 8
    Van Leeuwen FE, Benraadt J, Coebergh JWW,et al.Risk of endometrial cancer after tamoxifen treatment of breast cancer.Lancet1994; 343: 448452
  • 9
    Cutuli BF, Tritsch L, Jung GM, Mantz JMEmbolie pulmonaire mortelle chez une malade en cours de traitement adjuvant par tamoxifene.La Presse Medicale 1991; 20: 19481949
  • 10
    Nevasaari K, Heikkinen M, Taskinen PJTamoxifen and thrombosis.Lancet1978: i946947
  • 11
    Hendrick A, Subramanian VPTamoxifen and thromboembolism.JAMA 1980; 243: 514515
  • 12
    Wilson CB, Lambert HE, Scott RDSubclavian and axillary vein thrombosis following radiotherapy for carcinoma of the breast.Clin Radiol1987; 38: 9596
  • 13
    Fisher B, Costantino J, Redmond C,et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.N Engl J Med 1989; 320: 479484
  • 14
    Fisher B, Redmond C, Wickerham DL,et al.Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project Experience.J Clin Oncol 1989; 7: 572582
  • 15
    Saphner T, Tormey DC, Gray RVenous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.J Clin Oncol 1991; 9: 286294
  • 16
    McDonald CC, Alexander FE, Whyte BW, Forrest AP,Stewart HJ for the Scottish Cancer Trials Breast GroupBr Med J1995; 311: 977980
  • 17
    Tormey DC, Gray R, Falkson HCPostchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer.J Natl Cancer Inst 1996; 88: 18281833
  • 18
    Pritchard KI, Paterson AHG, Paul NA, Zee B, Fine S, Pater J,for the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site GroupJ Clin Oncol 1996; 14: 27312737
  • 19
    Fisher B, Dignam J, Bryant J,et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen-positive tumors.J Natl Cancer Inst 1996; 88: 15291542
  • 20
    Jick H, Jick SS, Derby LEValidation of information recorded on general practitioner based computerised data resource in the United Kingdom.Br Med J1991; 302: 766768
  • 21
    Jick H, Terris BZ, Derby LE, Jick SSFurther validation of information recorded on a general practitioner based computerized data resource in the United Kingdom.Pharmacoepidemiology and Drug Safety 1992; 1: 347349
  • 22
    Jick H, Jick S, Derby LE, Vasilakis C, Wald Myers M, Meier CRCalcium-channel blockers and risk of cancer.Lancet 1997; 349: 525528
  • 23
    Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis CRisk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.Lancet 1995; 346: 15891593
  • 24
    Cutuli B, Petit JC, Fricker JP, Schumacher C, Velten M, Abecassis JAccidents thromboemboliques chez les patientes menopausees sous traitement adjuvant par tamoxifene. Frequence, facteurs de risque et possibilites de prevention.Bull Cancer 1995; 82: 5156
  • 25
    Pemberton KD, Melissari E, Kakkar VVThe influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis.Blood Coagulation & Fibrinolysis1993; 4: 935942
  • 26
    Daly E, Vessey MP, Hawkins MM, Carlson JL, Gough P, Marsh SRisk of venous thromboembolism in users of hormone replacement therapy.Lancet 1996; 348: 977980
  • 27
    Jick H, Derby LE, Myers MW, Vasilakis C, Newton KMThe risk of hospitalization for idiopathic venous thromboembolism among users of postmenopausal estrogens.Lancet 1996; 348: 981983
  • 28
    Grodstein F, Stampfer MJ, Goldhaber SZ,et al.Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996;348: 983987
  • 29
    Pérez Gutthann S, Garca Rodrguez LA, Castellsague Pique J, Duque Oliart AHormone replacement therapy and risk of venous thromboembolism: population based case-control study.Br Med J1997; 314: 796800
  • 30
    Enck RE, Rios CNTamoxifen treatment of metastatic breast cancer and antithrombin III levels.Cancer 1984; 53: 26072609
  • 31
    Auger MJ, Mackie MJEffects of tamoxifen on blood coagulation.Cancer 1988; 61: 13161319
  • 32
    Love RR, Surawicz TS, Williams ECAntithrombin III level, fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy.Arch Intern Med 1992; 152: 317320
  • 33
    Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi UEffect of tamoxifen on measurements of hemostasis in healthy women.Arch Intern Med 1996; 156: 18061810